GeoVax Labs (GOVX)
(Real Time Quote from BATS)
$1.68 USD
-0.10 (-5.62%)
Updated Aug 8, 2024 09:44 AM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
GOVX 1.68 -0.10(-5.62%)
Will GOVX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GOVX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for GOVX
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
GeoVax Labs appoints Lambe to Scientific Advisory Board
Monkeypox plays make a comeback as WHO convenes emergency meeting
WHO to consider emergency as Mpox resurfaces in Africa, News Central reports
CDC says clinicians should remain alert for potential monkeypox cases